Department of Medicinal Chemistry, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, Hunan, China; Hunan Key Laboratory of Small Molecules for Diagnosis and Treatment of Chronic Disease, Changsha 410013, Hunan, China; Hunan Key Laboratory of Organ Fibrosis, Changsha 410013, Hunan, China.
Department of Medicinal Chemistry, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, Hunan, China; Hunan Key Laboratory of Small Molecules for Diagnosis and Treatment of Chronic Disease, Changsha 410013, Hunan, China; Hunan Key Laboratory of Organ Fibrosis, Changsha 410013, Hunan, China.
Drug Discov Today. 2023 May;28(5):103559. doi: 10.1016/j.drudis.2023.103559. Epub 2023 Mar 22.
Pulmonary arterial hypertension (PAH) is a currently incurable pulmonary vascular disease. Since current research on PAH is mainly aimed at the middle and late stages of disease progression, no satisfactory results have been achieved. This has led researchers to focus on the early stages of PAH. This review highlights for the first time a key event in the early stages of PAH progression, namely, the occurrence of pulmonary arterial smooth muscle cell (PASMC) phenotypic switching. Summarizing the related reports of phenotypic switching provides new perspectives and directions for the early pathological progression and treatment strategies for PAH.
肺动脉高压（PAH）是一种目前无法治愈的肺血管疾病。由于目前对 PAH 的研究主要集中在疾病进展的中晚期，因此没有取得令人满意的结果。这使得研究人员将注意力集中在 PAH 的早期阶段。本综述首次强调了 PAH 进展早期的一个关键事件，即肺动脉平滑肌细胞（PASMC）表型转换的发生。总结表型转换的相关报道，为 PAH 的早期病理进展和治疗策略提供了新的视角和方向。
